Education
About Us
Working with TipRanks
Follow Us
iX Biopharma Ltd. (SG:42C)
SGX:42C
42C Stock Chart & Stats
S$0.14
>-S$0.01(-4.00%)
At close: 4:00 PM EST
S$0.14
>-S$0.01(-4.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.25
Previous CloseN/A
Volume104.10K
Average Volume (3M)15.11M
Market Cap
S$198.06M
Enterprise ValueS$198.90M
Total Cash (Recent Filing)S$866.00K
Total Debt (Recent Filing)S$5.90M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,036,957,300
10 Day Avg. Volume11,332,920
30 Day Avg. Volume15,113,843
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)38.32
Price to Sales (P/S)1.80
P/FCF Ratio-3.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformOwning the WaferiX sublingual wafer platform gives the company a durable product differentiation. A platform technology can be applied across multiple therapeutics, enabling recurring licensing, easier product extensions and manufacturing leverage that support long-term commercial scalability and partner interest.
Partner-driven Commercialization ModelA business model built on licensing, partnerships and contract manufacturing reduces capital intensity and shifts commercialization risk to partners. Durable benefits include access to established distribution, milestone and royalty income, and scalable revenue with lower fixed selling costs if partnerships are executed.
Improving Product-level EconomicsAn improving gross margin alongside modest revenue growth indicates the core wafer products can generate positive unit economics. If management controls operating expenses, stronger gross margins provide a sustainable path to profitability over months as scale and partner rollouts reduce per-unit costs.
Bears Say
Persistent Large LossesVery large and persistent net losses undermine retained capital and strategic flexibility. Over the medium term these losses pressure ability to self-fund R&D, regulatory submissions and commercial rollouts, forcing dependence on external financing which can dilute shareholders and constrain long-term planning.
High Financial LeverageExtremely high debt relative to equity increases refinancing and interest-risk. High leverage reduces free cash flow available for investment, raises default vulnerability in adverse cycles, and limits capacity to fund new trials or scale manufacturing without costly external capital.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows with declining FCF growth indicate structural cash burn. This erodes runway for regulatory approvals and market launches, forces repeated financing rounds, and restricts the company’s ability to invest in commercialization or expand manufacturing capacity long term.
iX Biopharma Ltd. News
42C FAQ
What was iX Biopharma Ltd.’s price range in the past 12 months?
iX Biopharma Ltd. lowest share price was S$0.01 and its highest was S$0.25 in the past 12 months.
What is iX Biopharma Ltd.’s market cap?
iX Biopharma Ltd.’s market cap is S$198.06M.
When is iX Biopharma Ltd.’s upcoming earnings report date?
iX Biopharma Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 165 days.
How were iX Biopharma Ltd.’s earnings last quarter?
iX Biopharma Ltd. released its earnings results on Feb 08, 2026. The company reported -S$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.002.
Is iX Biopharma Ltd. overvalued?
According to Wall Street analysts iX Biopharma Ltd.’s price is currently Overvalued.
Does iX Biopharma Ltd. pay dividends?
iX Biopharma Ltd. does not currently pay dividends.
What is iX Biopharma Ltd.’s EPS estimate?
iX Biopharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iX Biopharma Ltd. have?
iX Biopharma Ltd. has 1,036,957,300 shares outstanding.
What happened to iX Biopharma Ltd.’s price movement after its last earnings report?
iX Biopharma Ltd. reported an EPS of -S$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.524%.
Which hedge fund is a major shareholder of iX Biopharma Ltd.?
Currently, no hedge funds are holding shares in SG:42C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
iX Biopharma Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
434.78%
12-Months-Change
Fundamentals
Return on Equity
-450.81%
Trailing 12-Months
Asset Growth
21.42%
Trailing 12-Months
Company Description
iX Biopharma Ltd.
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body's NAD+ levels, energy levels, and alertness; iXB 120 that has completed Phase I clinical trial for acute agitation; IXB-214, which has completed Phase I clinical trial for complex regional pain syndrome; and IXB-314 that has completed Phase I clinical trial for treatment resistant depression. In addition, it develops BnoX that is in a phase-1 clinical trial for moderate to severe pain; NAD+ for sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafe for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer for skin brightening and immunity. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.
Technical Analysis
Hyphens Pharma International Ltd.
―
Pharmesis International Ltd.
―
Singapore Paincare Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Beverly JCG Ltd.
―
Options Prices
Currently, No data available
---